A major focus of current treatment research in schizophrenia is the determinants of long-term
outcome, including functional outcome and general medical well being, rather than just …

Objective: Childhood-onset schizophrenia (COS) is a rare but severe form of the disorder,
which is often treatment refractory. Short-term studies have indicated a greater differential …

It has been suggested that atypical antipsychotic drugs (A-APDs) other than clozapine may
be effective to improve positive symptoms in some patients with treatment resistant …

Dopamine supersensitivity psychosis (DSP) is a key factor contributing to the development
of antipsychotic treatment-resistant schizophrenia. We examined the efficacy and safety of …

When it comes to the use of psychotropic agents in pediatric patients, it is not merely a
question of extrapolating data from adults to children and adolescents; special consideration …

BackgroundImprovements are greatest in the earlier weeks of antipsychotic treatment of
patients with non-resistant schizophrenia. AimsTo address the early time-line for …

Schizophrenia is a chronic illness with a progressive course that can be marked by
resistance to antipsychotic treatment. This can make therapeutic support challenging for the …

Schizophrenia is manifested by positive and negative symptoms, as well as cognitive
deficits. Most existing antipsychotic agents have poor effects on the negative symptoms of …

Despite the availability of atypical antipsychotics, the treatment of negative symptoms in
schizophrenia remains a challenge. This study was designed to confirm the positive effect …

Aims: The objective of the study was to examine the efficacy and the degree of adverse
effects connected with atypical neuroleptic drugs and haloperidol by using a previously …